Crossmark

Engineered anti-CRISPR proteins for optogenetic control of CRISPR–Cas9

Crossref DOI link: https://doi.org/10.1038/s41592-018-0178-9

Published Online: 2018-10-30

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bubeck, Felix

Hoffmann, Mareike D.

Harteveld, Zander https://orcid.org/0000-0002-2069-069X
Aschenbrenner, Sabine

Bietz, Andreas

Waldhauer, Max C.

Börner, Kathleen

Fakhiri, Julia

Schmelas, Carolin

Dietz, Laura

Grimm, Dirk

Correia, Bruno E. https://orcid.org/0000-0002-7377-8636
Eils, Roland https://orcid.org/0000-0002-0034-4036
Niopek, Dominik https://orcid.org/0000-0001-7479-530X
License Information

Text and Data Mining valid from 2018-10-30
More Information

Article History

Received: 11 May 2018

Revised: 8 August 2018

Accepted: 8 August 2018

First Online: 30 October 2018

Competing interests

: F.B., M.D.H., A.B., M.C.W., J.F., L.D., D.G., R.E. and D.N. have filed European patent applications (17196813.4) related to this work.